Preclinical drug safety
Precision safety insights for preclinical studies using LiquiPath™
The challenge
Preclinical safety is expensive, slow, and translates poorly
Current approaches rely on slow histopathology, prior knowledge of toxicity risks, and often miss key toxicokinetic signals. The result is limited mechanistic insight and compound misclassification, delaying development and increasing risk.
<10% of drugs that make it through preclinical testing reach the market
Rodent studies for oncology drugs cost $2-4M and add 4-5 years to development
Current preclinical safety models are poor predictors of human drug safety
Our solution
Real-time organ health
LiquiPath redefines how we can monitor preclinical drug safety. For the first time, a single blood sample can provide real-time insight into treatment response across multiple organs, reducing reliance on slow and costly histopathology.
Unmatched insights
Our multi-tissue monitoring approach enables early detection of toxicity signals, shortening time-to-readout for preclinical safety studies. By uncovering toxicokinetic profiles and the mechanisms driving adverse events, LiquiPath aims to supports seamless translation from preclinical to clinical studies.
-
LiquiPathTraditional approaches
-
Multi-organ monitoring without histopathology
-
Cost-effective
-
Faster decisions
-
Streamlined and non-invasive
-
Mechanistic insights
-
Integrated efficacy & safety monitoring
-
Seamless translation to clinical settings
Join the revolution
Early access customers will have the opportunity to shape the capabilities of our organ health platform before general availability
Contact us to learn more about how we can improve your safety monitoring approach
Contact us